We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
(-2.6%)
Cap. Flow
-$4.15B
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$309M |
| 2 |
ExxonMobil
XOM
|
+$302M |
| 3 |
Amazon
AMZN
|
+$291M |
| 4 |
Citigroup
C
|
+$253M |
| 5 |
Shopify
SHOP
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$383M |
| 2 |
Johnson & Johnson
JNJ
|
+$312M |
| 3 |
JPMorgan Chase
JPM
|
+$285M |
| 4 |
AT&T
T
|
+$191M |
| 5 |
Dollar General
DG
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.63% |
| 2 | Financials | 15.61% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 13.21% |
| 5 | Industrials | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Fortive
FTV
$19B
| $159M | 0.36% |
3,287,077
+174,820
| +6% | +$8.47M |
|
52
AstraZeneca
AZN
$263B
| $158M | 0.36% |
1,168,620
+266,954
| +30% | +$33.5M |
|
53
Ross Stores
ROST
$76.6B
| $158M | 0.36% |
1,362,603
+1,222,789
| +875% | +$125M |
|
54
Union Pacific
UNP
$183B
| $157M | 0.35% |
757,495
+118,052
| +18% | +$24.2M |
|
55
Starbucks
SBUX
$118B
| $156M | 0.35% |
1,568,343
+547,060
| +54% | +$51.6M |
|
56
Cisco
CSCO
$450B
| $155M | 0.35% |
3,250,224
-668,954
| -17% | -$30.4M |
|
57
PUT
Invesco QQQ Trust
QQQ
$455B
| $150M | 0.34% |
562,200
+350,100
| +165% | +$96.8M |
|
58
Adobe
ADBE
$89.5B
| $147M | 0.33% |
438,052
+359,791
| +460% | +$115M |
|
59
Interactive Brokers
IBKR
$40.9B
| $147M | 0.33% |
8,111,272
-4,656,668
| -36% | -$87M |
|
60
Nucor
NUE
$56.4B
| $147M | 0.33% |
1,111,646
+670,178
| +152% | +$91.1M |
|
61
Stellantis
STLA
$16.5B
| $144M | 0.32% |
10,201,785
-5,553,729
| -35% | -$77.3M |
|
|
CMA
62
DELISTED
Comerica
CMA
| $141M | 0.32% |
2,109,181
-267,847
| -11% | -$18.6M |
|
63
Baxter International
BAX
$11.6B
| $138M | 0.31% |
2,708,519
+156,241
| +6% | +$8.39M |
|
64
Vulcan Materials
VMC
$36.3B
| $134M | 0.3% |
767,685
-44,271
| -5% | -$7.57M |
|
65
Lamb Weston
LW
$6.82B
| $132M | 0.3% |
1,474,110
-658,233
| -31% | -$56M |
|
66
J.M. Smucker
SJM
$12.6B
| $130M | 0.29% |
818,287
+480,979
| +143% | +$71.7M |
|
67
PUT
SPDR Gold Trust
GLD
$131B
| $128M | 0.29% |
756,900
+501,300
| +196% | +$80.7M |
|
68
Mastercard
MA
$477B
| $126M | 0.28% |
362,452
-203,369
| -36% | -$66.9M |
|
|
CNH
69
CNH Industrial
CNH
$13.8B
| $125M | 0.28% |
7,856,477
-4,666,924
| -37% | -$67.2M |
|
70
Cboe Global Markets
CBOE
$29.8B
| $125M | 0.28% |
996,177
-295,736
| -23% | -$36.5M |
|
71
Fortinet
FTNT
$112B
| $123M | 0.28% |
2,507,678
-2,343,598
| -48% | -$122M |
|
72
Procter & Gamble
PG
$343B
| $122M | 0.27% |
805,264
+804,637
| +128,331% | +$113M |
|
73
Cloudflare
NET
$93B
| $120M | 0.27% |
2,644,109
+2,588,707
| +4,673% | +$128M |
|
|
BNY
74
Bank of New York Mellon
BNY
$108B
| $119M | 0.27% |
2,623,663
+895,183
| +52% | +$38.4M |
|
75
Vertex Pharmaceuticals
VRTX
$121B
| $118M | 0.27% |
410,021
+136,169
| +50% | +$41.5M |
|
Similar funds
Marshall Wace's Q4 2022 Portfolio in Review
As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.
- Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
- Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
- Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
- Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
- Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
- Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.